Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort.
Fiche publication
Date publication
août 2024
Journal
JHEP reports : innovation in hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MINELLO Anne
Tous les auteurs :
de Lédinghen V, Fougerou-Leurent C, Le Pabic E, Pol S, Alfaiate D, Lacombe K, Hilleret MN, Lascoux-Combe C, Minello A, Billaud E, Rosa I, Gervais A, Ratziu V, Ganne N, Pageaux GP, Leroy V, Loustaud-Ratti V, Mathurin P, Chas J, Jezequel C, Métivier S, Dumortier J, Arpurt JP, Asselah T, Roche B, Le Gruyer A, Valantin MA, Scholtès C, Gordien E, Tual C, Kortebi A, Coulibaly F, Rosenthal E, Subic-Levrero M, Roulot D, Zoulim F,
Lien Pubmed
Résumé
In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV coinfection.
Mots clés
Cirrhosis, Entry inhibitors, HBV, HBV DNA, HDV, HDV RNA, HIV, HIV RNA, Hepatitis D, Pegylated interferon
Référence
JHEP Rep. 2024 08;6(8):101057